利奈唑胺（linezolid）是第一個臨床應(yīng)用的新型唑烷酮類抗生素，通過抑制細菌蛋白質(zhì)的合成達到抑菌的作用。因利奈唑胺獨特的作用位點和方式，故不易與其他基于抑制蛋白合成發(fā)揮抗菌作用的藥物發(fā)生交叉耐藥，而本身也不易誘導(dǎo)產(chǎn)生耐藥性，其臨床療效已經(jīng)得到一系列III期臨床研究證明?，F(xiàn)就其作用機制、兒科臨床應(yīng)用及不良反應(yīng)進行綜述。

Linezolid is the first new antibiotics of oxazolidinone class in clinical application to play inhibitory effect by inhibiting bacterial protein synthesis. Linezolid has the unique site and way of action so it is not easy to produce cross-resistance with other antimicrobial that could inhibit protein synthesis and induce the resistance in vivo. Its clinical efficacy has been shown in a series of phase III clinical studies. This article reviews its mechanism of action, clinical applications, and adverse reactions in pediatrics.